Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1128/AAC.00509-12 | ||||
| Año | 2012 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Mutations in liaFSR, a three-component regulatory system controlling cell-envelope stress response, were recently linked with the emergence of daptomycin (DAP) resistance in enterococci. Our previous work showed that a liaF mutation increased the DAP MIC of a vancomycin-resistant Enterococcus faecalis strain from 1 to 3 mu g/ml (the DAP breakpoint is 4 mu g/ml), suggesting that mutations in the liaFSR system could be a pivotal initial event in the development of DAP resistance. With the hypothesis that clinical enterococcal isolates with DAP MICs between 3 and 4 mu g/ml might harbor mutations in liaFSR, we studied 38 Enterococcus faecium bloodstream isolates, of which 8 had DAP MICs between 3 and 4 mu g/ml by Etest in Mueller-Hinton agar. Interestingly, 6 of these 8 isolates had predicted amino acid changes in the LiaFSR system. Moreover, we previously showed that among 6 DAP-resistant E. faecium isolates (MICs of >4 mu g/ml), 5 had mutations in liaFSR. In contrast, none of 16 E. faecium isolates with a DAP MIC of <= 2 mu g/ml harbored mutations in this system (P < 0.0001). All but one isolate with liaFSR changes exhibited DAP MICs of >= 16 mu g/ml by Etest using brain heart infusion agar (BHIA), a medium that better supports enterococcal growth. Our findings provide a strong association between DAP MICs within the upper susceptibility range and mutations in the liaFSR system. Concomitant susceptibility testing on BHIA may be useful for identifying these E. faecium first-step mutants. Our results also suggest that the current DAP breakpoint for E. faecium may need to be reevaluated.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | MUNITA-SEPULVEDA, JOSE MANUEL | Hombre |
Univ Texas Med Sch Houston - Estados Unidos
Universidad del Desarrollo - Chile University of Texas Medical School at Houston - Estados Unidos Clínica Alemana - Chile |
| 2 | Panesso, Diana | Mujer |
Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia University of Texas Medical School at Houston - Estados Unidos Universidad El Bosque - Colombia |
| 3 | Diaz, Lorena | Mujer |
Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia University of Texas Medical School at Houston - Estados Unidos Universidad El Bosque - Colombia |
| 4 | Tran, Truc T. | Mujer |
Univ Texas Med Sch Houston - Estados Unidos
UNIV HOUSTON - Estados Unidos University of Texas Medical School at Houston - Estados Unidos University of Houston - Estados Unidos |
| 5 | Reyes, Jinnethe | - |
Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia University of Texas Medical School at Houston - Estados Unidos Universidad El Bosque - Colombia |
| 6 | Wanger, Audrey | Mujer |
Univ Texas Med Sch,Houston - Estados Unidos
University of Texas Medical School at Houston - Estados Unidos Univ Texas Med Sch Houston - Estados Unidos |
| 7 | Murray, Barbara | Mujer |
Ctr Study Emerging & Reemerging Pathogens - Estados Unidos
Univ Texas Med Sch,Houston - Estados Unidos Univ Texas Med Sch Houston - Estados Unidos Center for the Study of Emerging and Reemerging Pathogens - Estados Unidos University of Texas Medical School at Houston - Estados Unidos |
| 8 | Arias, Cesar A. | Hombre |
Univ Texas Med Sch Houston - Estados Unidos
Ctr Study Emerging & Reemerging Pathogens - Estados Unidos Univ El Bosque - Colombia University of Texas Medical School at Houston - Estados Unidos Center for the Study of Emerging and Reemerging Pathogens - Estados Unidos Universidad El Bosque - Colombia |
| Fuente |
|---|
| NIH |
| National Institute of Allergy and Infectious Diseases |
| Johnson Johnson |
| Pfizer, Inc. |
| Astellas |
| Cubist |
| NIH from the National Institute of Allergy and Infectious Diseases (NIAID) |
| Palumed |
| Intercell |
| Forrest Pharmaceuticals |
| Agradecimiento |
|---|
| Cesar A. Arias has received lecture fees, research support, and consulting fees from Pfizer, Inc., and Cubist and research support from Forrest Pharmaceuticals and has served as speaker for Novartis. Barbara E. Murray received grant support from Johnson & Johnson, Astellas, Palumed, Intercell, and Cubist, and has served as consultant for Astellas (Theravance), Cubist, Targanta Therapeutics (now owned by The Medicines Company), Pfizer, The Medicines Company, Rib-X, and Durata Therapeutics. |